In the last trading session, 1.18 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.38. With the company’s per share price at $1.44 changed hands at $0.0 or 0.00% during last session, the market valuation stood at $327.12M. ADAP’s last price was a discount, traded about -42.36% off its 52-week high of $2.05. The share price had its 52-week low at $0.42, which suggests the last value was 70.83% up since then. When we look at Adaptimmune Therapeutics Plc ADR’s average trading volume, we note the 10-day average is 1.53 million shares, with the 3-month average coming to 1.91 million.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
With action -2.04%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 81.59%, with the 5-day performance at -2.04% in the red. However, in the 30-day time frame, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) is -2.70% down. Looking at the short shares, we see there were 2.8 million shares sold at short interest cover period of 1.03 days.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
Data shows that the Adaptimmune Therapeutics Plc ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 84.03% over the past 6 months, a 30.16% in annual growth rate that is considerably higher than the industry average of 12.20%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Adaptimmune Therapeutics Plc ADR will fall -1,100.00%, while the growth in revenue is estimated to hit 50.00% for the next quarter. Year-over-year growth is forecast to reach 16.20% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of $5.63 million. 7 analysts are of the opinion that Adaptimmune Therapeutics Plc ADR’s revenue for the quarter ending Jun 2024 will be $22.97 million. The company’s revenue for the corresponding quarters a year ago was $47.6 million and $5.13 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -88.20%. The estimates for the next quarter sales put growth at 347.80%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.30%. The 2024 estimates are for Adaptimmune Therapeutics Plc ADR earnings to decrease by -327.78%, but the outlook for the next 5-year period is at 1.00% per year.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR is expected to release its next quarterly earnings report on March 06.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.21% of Adaptimmune Therapeutics Plc ADR shares while 66.57% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 66.71%. There are 66.57% institutions holding the Adaptimmune Therapeutics Plc ADR stock share, with Matrix Capital Management the top institutional holder. As of Jun 29, 2023, the company held 25.20% of the shares, roughly 38.97 million ADAP shares worth $36.05 million.
Baillie Gifford and Company holds the second largest percentage of outstanding shares, with 11.11% or 17.18 million shares worth $15.89 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jul 30, 2023 were Old Westbury Small & Mid Cap Strategies Fund and iShares NASDAQ Biotechnology ETF. With 2.4 million shares estimated at $2.26 million under it, the former controlled 1.55% of total outstanding shares. On the other hand, iShares NASDAQ Biotechnology ETF held about 0.55% of the shares, roughly 0.84 million shares worth around $0.66 million.
